Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

personal-95715_640

Mirror. Signal. Merger. How to deal with a pharma takeover

December 14, 2015 Manufacturing and Production, Medical Communications, Sales and Marketing Deals, acquisition, buyouts, mergers, takeovers

So 2015 has been a record year for M&A in the pharma industry.The Financial Times has called this “the most …
Feature
AZ building

AstraZeneca in $5bn Acerta buyout talks

December 14, 2015 Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, blood cancer, buyout, chronic lymphocytic leukaemia, mergers, takeover

AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …
News
Chest x ray

Roche lung cancer drug Alecensa gets rapid US approval

December 14, 2015 Sales and Marketing Alecensa, FDA, Genentech, Roche, accelerated approval, alectinib, lung cancer, non-small cell lung cancer

The US health watchdog has approved Alecensa, a drug for people with certain types of non-small cell lung cancer manufactured …
News
Novartis image

Novartis earns provisional NICE yes for Entresto

December 11, 2015 Sales and Marketing Entresto, NICE, Novartis, chronic heart failure, heart failure

NICE has indicated it is likely to recommend Entresto, a novel drug manufactured by Novartis, as a treatment option for …
News
labcorps_purchase_of_covance_topped_the_outsourcing_deals_in_2015

M&A activity drives record year for pharma outsourcing deals

December 11, 2015 Sales and Marketing Covance, M&A, MA, labcorp, outsourcing

A drastic increase pharma industry in M&A activity has propelled the value of pharmaceutical outsourcing deals from $9.9 billion in …
News
halaven

Eisai’s Halaven shown to restrict further cancer metastasis

December 11, 2015 Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda

New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …
News
Lynparza

NICE recommends AstraZeneca’s Lynparza after price reduction

December 11, 2015 Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer

NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …
News

NICE publishes draft guidance on two prostate cancer treatments

December 11, 2015 Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
News
Novolog pen

Novo Nordisk files for new insulin approval

December 10, 2015 Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application

Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …
News
cindy_whitehead

‘Female Viagra’ CEO leaves company

December 10, 2015 Medical Communications, Sales and Marketing Addyi, Cindy Whitehead, Sprout Pharma

Cindy Whitehead has left Sprout Pharmaceuticals, just four months after guiding the female libido drug Addyi to FDA approval and overseeing …
Appointment
Janssen image

Janssen submits Stelara for EU approval for Crohn’s

December 9, 2015 Sales and Marketing Crohn’s disease, EMA, European Medicines Agency, Janssen, Stelara, crohn's disease, ustekinumab

Janssen today announced that it has submitted an application to the European Medicines Agency, seeking approval of Stelara in Crohn’s …
News
mark_forbes_irving

Former Quintiles director joins IDEA Pharma as MD

December 9, 2015 Medical Communications, Sales and Marketing IDEA Pharma, Mark Forbes Irving

IDEA Pharma has appointed Mark Forbes Irving as managing director. With over 20 years’ industry experience, the new managing director joins …
Appointment
Scotland flag

Cancer and MS drugs approved in Scotland

December 9, 2015 Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia

The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …
News
Pfizer CEO Ian Read

Five benefits and challenges of the Pfizer/Allergan mega-merger

December 7, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Pfizer, acquisitions, mergers, takeovers

Pfizer was extremely keen to get the $160 billion deal done, but what is it getting out of the acquisition, …
Feature
Merck image

Late-stage failure for Merck and Threshold cancer drug

December 7, 2015 Research and Development, Sales and Marketing Merck, Pancreatic cancer, Threshold Pharmaceuticals, evofosfamide, late-stage failure, phase III, sarcoma

Merck and its development partner Threshold Pharmaceuticals say they will not pursue regulatory approval for evofosfamide in advanced soft tissue …
News
The Gateway to Local Adoption Series

Latest content

Stage4You encourages stage 4 bowel cancer patients to prioritise mental health ahead of Bowel Cancer Awareness Month

March 26, 2026

Scotland starts newborn screening for SMA

March 26, 2026

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026